Scientific communications

Mixed Lymphocyte Reaction for novel cancer immunotherapy testing

10 / 18 / 2018

The immunological synapse that occurs between T lymphocytes and Dendritic cells (DCs) is a key component of an effective immune response and is controlled by a combination of stimulatory and inhibitory signals – also called immune checkpoints. As to trigger a better anti-tumor immune response, interventions through a fine-tuning of these control signals within the immunological synapse represent one of the most promising cancer immunotherapy strategies.

Quantitative in vitro assays for pharmacological characterization of PD1/PDL1 and CTLA4 immune checkpoint blockade

09 / 19 / 2018

Activation of T cell immune response through regulation of immune checkpoint pathways is one of the most considerable strategies being employed in cancer immunotherapy, either as individual or in combination. While development of checkpoint inhibitors blocking PD1/PDL1 interaction is still a major interest thereby contributing to the suppression of tumor immune resistance, accurate identification and robust pharmacological characterization of modulatory agents thus become key and should be guaranteed through the assays.

In Vitro Immune Cell Activation

02 / 19 / 2018

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Upon activation, immune (T) cells undergo clonal expansion followed by differentiation into effectors to mediate cytotoxicity and/or cytokine release. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.

Immunosuppressive Tumor Microenvironment In OT 4T1 Breast Tumor Model

10 / 16 / 2017

While known and validated as non-responsive to conventional immune checkpoint inhibitors, our OT syngeneic mammary tumor model, which represents an aggressive model of human breast carcinoma, is characterized by the presence of at least two types of tumor-infiltrating immunosuppressive cells – myeloid suppressive cells (MSC) and T regulatory cells (Treg). Such cell populations are known, as a result, to suppress effector immune cell responses, thereby promoting tumor immune escape and metastasis.